FDA Class II Recall: A-S Medication Solutions' Metformin HCl ER Contaminated with Foreign Tablets
A-S Medication Solutions LLC initiated a Class II recall for 411 bottles of Metformin Hydrochloride Extended-Release 500mg due to foreign tablets/capsules. This voluntary action, impacting nationwide U.S. distribution, signals critical quality control gaps for procurement and regulatory teams. Businesses must assess their supply chain exposure to A-S Medication Solutions and verify product integrity to mitigate patient safety risks and ensure compliance.
FDA Class II Recall: Foreign Tablets Found in A-S Medication Solutions' Metformin HCl ER
A-S Medication Solutions LLC has initiated a voluntary Class II recall for specific lots of its Metformin Hydrochloride Extended-Release 500mg tablets, distributed nationwide across the United States. The critical reason for this recall, identified as D-0292-2025, is the confirmed presence of foreign tablets or capsules within the product packaging. This poses a direct risk to patient safety, as individuals prescribed Metformin Hydrochloride for diabetes management could inadvertently ingest an incorrect medication, leading to adverse health consequences or ineffective treatment. The recall specifically targets 411 180-count bottles of Metformin Hydrochloride Extended-Release 500mg, identified by NDC 50090-1494-3, from Lot# 4260340, with an expiration date of December 31, 2025. This event, initiated by the firm on February 25, 2025, and classified by the FDA on March 21, 2025, is currently ongoing. For procurement directors and supply chain VPs, this incident necessitates immediate action to quarantine affected stock and assess the integrity of all incoming shipments from A-S Medication Solutions, particularly for this critical diabetes medication. The Class II classification indicates that while exposure may cause temporary or medically reversible adverse health consequences, the probability of serious adverse consequences is remote, yet the risk remains significant for vulnerable patient populations.
A-S Medication Solutions: Product and Packaging Operations Under Scrutiny
A-S Medication Solutions LLC, based in Libertyville, Illinois, operates as a packager and distributor of human prescription drugs. This recall highlights potential vulnerabilities in their quality control processes, specifically concerning packaging lines for high-volume generic medications like Metformin Hydrochloride. The recalled product, Metformin Hydrochloride Extended-Release 500mg, is a widely used oral antidiabetic drug, approved under ANDA201991. Its generic nature means it is a staple in many pharmacy and hospital formularies, making any contamination issue a broad concern. The product's National Drug Code (NDC) is 50090-1494, with specific packaging identified by 50090-1494-3, and the original packager’s NDC was 67877-159. For regulatory affairs heads, this event underscores the importance of robust supplier qualification and ongoing auditing, especially for repackaging facilities. The presence of foreign tablets suggests a breakdown in segregation protocols or cleaning validation, critical aspects of Current Good Manufacturing Practices (cGMP). Businesses relying on A-S Medication Solutions for repackaged pharmaceuticals must scrutinize their quality agreements and conduct thorough risk assessments to ensure that similar contamination risks are not present across other product lines or batches.
Commercial Implications and Supply Chain Vigilance for Metformin Sourcing
The ongoing Class II recall of Metformin Hydrochloride Extended-Release 500mg by A-S Medication Solutions LLC carries significant commercial implications for pharmaceutical companies, distributors, and healthcare providers. For procurement teams, the immediate concern is securing an uninterrupted supply of Metformin, a foundational drug for type 2 diabetes. While the recalled quantity of 411 bottles may seem modest, the nature of the defect—foreign tablets—raises questions about the broader integrity of A-S Medication Solutions' packaging operations. Supply chain VPs must initiate a comprehensive review of all products sourced from A-S Medication Solutions, not just Metformin, to proactively identify and mitigate potential contamination risks. This includes assessing the impact on downstream formulators and pharmacies that may have received affected lots. Business development executives should note that such quality incidents can erode trust and necessitate a re-evaluation of supplier relationships, potentially leading to shifts in market share towards manufacturers with more robust quality systems. Given the nationwide distribution, the recall's ripple effects could extend to numerous healthcare providers, impacting patient care and potentially leading to product returns and reputational damage for all entities in the supply chain. Continuous monitoring of the FDA's updates on this recall (D-0292-2025) is crucial for informed decision-making and risk management.